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Abstract
The complexity of human cancer often results in significant heterogeneity in response to treatment.
Precision medicine offers potential to improve patient outcomes by leveraging this heterogeneity.
Individualized treatment rules (ITRs) formalize precision medicine as maps from the patient co-
variate space into the space of allowable treatments. The optimal ITR is that which maximizes the
mean of a clinical outcome in a population of interest. Patient-derived xenograft (PDX) studies
permit the evaluation of multiple treatments within a single tumor and thus are ideally suited for
estimating optimal ITRs. PDX data are characterized by correlated outcomes, a high-dimensional
feature space, and a large number of treatments. Existing methods for estimating optimal ITRs
do not take advantage of the unique structure of PDX data or handle the associated challenges
well. In this paper, we explore machine learning methods for estimating optimal ITRs from PDX
data. We analyze data from a large PDX study to identify biomarkers that are informative for de-
veloping personalized treatment recommendations in multiple cancers. We estimate optimal ITRs
using regression-based approaches such as Q-learning and direct search methods such as outcome
weighted learning. Finally, we implement a superlearner approach to combine a set of estimated
ITRs and show that the resulting ITR performs better than any of the input ITRs, mitigating
uncertainty regarding user choice of any particular ITR estimation methodology. Our results in-
dicate that PDX data are a valuable resource for developing individualized treatment strategies in
oncology.
Keywords: Biomarkers, Deep learning autoencoders, Machine learning, Outcome weighted learn-
ing, Precision medicine, Patient-derived xenografts, Q-learning
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1. INTRODUCTION
The complexity of human cancer is reflected in the molecular and phenotypic diversity of patient
tumors (Polyak, 2011). This diversity results in heterogeneity in response to treatment, which
complicates clinical decision making. The complexity of human cancer is also reflected in the high
failure rate of new therapies entering oncology clinical trials, highlighting limitations in the ability of
standard preclinical models to evaluate new therapies (Tentler et al., 2012). A recent study utilized
patient-derived xenografts (PDXs) to perform a large-scale screening in mice to evaluate a large
number of FDA-approved and preclinical cancer therapies (Gao et al., 2015). Genomic information
and observed treatment responses were used to identify efficacious therapies that standard cell line
model systems had missed, and also validate known associations between genomic biomarkers and
differential response to treatment. The results from this PDX study mirrored those seen in human
patients. Thus, PDX models can be used to evaluate in vivo therapeutic response and discover
novel biomarkers to inform individualized treatment decisions.
PDX models are based on the transfer of primary human tumors directly from the patient into
an immunodeficient mouse (Siolas and Hannon, 2013). Briefly, pieces of primary solid tumors are
collected from patients by surgery or biopsy (Hidalgo et al., 2014). The collected tumor pieces from
an individual patient are then implanted into mice subcutaneously to create a PDX line, whereby
tumor size and rate of tumor growth after implantation may be measured over time. After the
tumor reaches sufficient size, the line may be expanded by passaging directly from the implanted
tumor into additional genetically identical mice. Through this expansion, multiple treatments may
be applied to mice originating from the same PDX line, allowing for the application of multiple
treatments to the same patient tumor. High throughput genomic assays such as RNA sequencing
(RNA-seq) and DNA sequencing may be performed on the original patient tumor. Features of the
original tumor will be retained throughout line expansions (Hidalgo et al., 2014), making PDX
models ideal for learning how to personalize cancer treatment, given observed feature-response
associations.
Personalized treatment recommendations in oncology have traditionally centered around the
classification of patients into subgroups (Sargent et al., 2005). In some cases, patient subgroups
may be derived from predictive models based upon genomic biomarkers (Parker et al., 2009).
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Yet, significant heterogeneity in treatment response may still be observed within such subgroups
(Metzger-Filho et al., 2012; Chen et al., 2014), and assignment of optimal treatment is predicated
upon accurate subgroup prediction. An alternative approach to precision medicine is the estimation
of an individualized treatment rule (ITR), a map directly from the patient covariate space to the
space of allowable treatments that can be used to make treatment decisions. The optimal ITR is
defined as the one that maximizes the mean of a clinical outcome, such as treatment response, when
applied in a population. Examples of such covariates may include patient clinical information, such
as laboratory assay results, or high dimensional genomic data, such as gene expression or mutation
data from a patient’s tumor. As such, treatment recommendations based upon an optimal ITR
may result in improved clinical outcomes by harnessing individual-specific molecular and clinical
features not captured by subgroup-based approaches.
A number of methods have been proposed to estimate an optimal ITR. One approach is to fit
a regression model for treatment response given a set of applied treatments and patient covariate
information. The optimal treatment is then the one providing the maximum predicted response in a
new patient, given the fitted regression model and the covariate information for that patient (Qian
and Murphy, 2011). An example of this approach is Q-learning (Murphy, 2005; Zhao et al., 2009;
Qian and Murphy, 2011; Schulte et al., 2014). Direct search methods, including outcome weighted
learning (OWL) (Zhao et al., 2012; Zhou et al., 2017; Liu et al., 2016; Chen et al., 2017), doubly
robust ITR estimators (Zhang et al., 2012, 2013), and marginal structural models (Robins et al.,
2008; Orellana et al., 2010) estimate the optimal ITR using inverse probability weighting rather than
regression. In direct search methods, the class of ITRs is prespecified, while in other approaches,
the class of ITRs is implied by the modeling process. Recent advances in machine learning for
causal inference have produced a number of estimators for the conditional average treatment effect
that could be used to estimate an ITR for a binary treatment decision (Imai et al., 2013; Athey
and Imbens, 2016; Wager and Athey, 2018). Other methods for estimating optimal ITRs include
marginal mean models (Murphy et al., 2001) and Bayesian predictive modeling (Ma et al., 2016).
Regardless of the approach, many existing methods may directly utilize high-dimensional genomic
biomarker data. However, such methods were not designed for PDX studies, where the application
of multiple treatments within a subject (PDX line) results in correlated outcomes, and the number
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of available treatments is large.
In this manuscript, we utilize the wealth of clinical and biomarker data generated by the Novartis
PDX study (Gao et al., 2015) to estimate optimal ITRs for treating several human cancers. Given
the correlated outcomes within PDX lines, the large number of treatments, and the high dimension
of the covariate space, it is difficult to fit a nonparametric model to the conditional mean response
without large amounts of data. Thus, we explore a number of ways of imposing structure on
the conditional mean response, including reducing the dimension of the covariate space, grouping
treatments that result in a similar mean response, and constructing a treatment tree to convert the
problem of selecting from a large set of treatments to a sequence of binary comparisons. The result
is a multi-step procedure, where each step can be thought of as imposing structure on the model
for the conditional mean response in a way that alleviates the challenges posed by PDX data and
takes advantage of the unique structure of PDX data. Such multi-step procedures are well-studied
and have shown good performance in many applications (Love et al., 2014; Bourgon et al., 2010;
Soneson and Delorenzi, 2013; Rashid et al., 2014). We show that the proposed multi-step procedure
achieves improved performance over standard methods in certain settings. We examine the various
modeling decisions that are made at each step of the multi-step procedure and demonstrate the
use of super-learning (Luedtke and van der Laan, 2016) to improve prediction performance by
aggregating the proposed models.
In Section 2, we describe the large-scale PDX data set that motivated this work and use it to
highlight the challenges associated with estimating optimal ITRs using PDX data. We present our
methodological approaches in Section 3. We present results from our data analyses in Section 4. In
Section 5, we conclude with a discussion to compare and contrast the various modeling decisions
we made and discuss the clinical implications of our findings. Additional details, including software
for reproducing our work, are given in the Supplemental Materials.
2. LARGE-SCALE PDX DRUG SCREEN FOR TREATMENT RESPONSE
2.1 Data Overview
The Novartis PDX study (Gao et al., 2015) established a total of 1075 PDX lines corresponding to
a variety of human cancers. A subset of these lines were genomically profiled prior to treatment for
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gene expression (399 lines), copy number analysis (375), and mutations (399). In addition, 281 lines
were enrolled in the drug response study. Our study utilizes 190 PDX lines with complete genomic
and response data (Supplementary Figure 1). Five types of cancer are represented among these 190
lines (Supplementary Figure 2): breast cancer (BRCA), melanoma (CM), colorectal cancer (CRC),
non-small cell lung cancer (NSCLC), and pancreatic cancer (PDAC). A median of 21 treatments
were applied per PDX line across different cancers (Supplementary Figure 2). Certain PDX lines
had fewer mice and therefore fewer treatments than the total number of treatments available for
a particular cancer type. One mouse per PDX line was set as a control line and did not receive
treatment.
In total, 3487 mice, expanded from the 190 PDX lines with complete data, were used for our
study. Details regarding the biomarker data utilized in this study are given in Section 6 of the
Supplemental Materials. Briefly, each of the 190 PDX lines had 22,665 genes measured for gene
expression via RNA-seq, 23,854 genes measured for gene-level copy number estimates via copy
number array, and between 159 and 293 mutations (25th and 75th percentiles) identified via DNA
sequencing. In total, a union set of approximately 60,000 features are available for ITR estimation.
Because each genomic assay was performed on the patient tumor prior to implantation, all mice
expanded from the same PDX line share the same set of genomic biomarkers.
2.2 Study Design and Response Variables
Mice from each PDX line were treated with either single agents or combinations. A total of 38
unique therapies were applied, administered either as a single agent (36 total administered) or
in combination with other agents (26 total combinations administered). Certain treatments were
limited to particular cancers, whereas others were applied across cancers. Each mouse was treated
for a minimum of 21 days. Tumor size was evaluated twice weekly by caliper measurements, and
the approximate volume of the tumor was calculated using the formula (l×w×w)× (pi/6), where
l is the major tumor axis and w is the minor tumor axis.
Two measures were utilized to summarize response to treatment: best average response (BAR)
and time to tumor doubling (TTD). BAR is defined as mint:dt>10
[{1/(t+ 1)}∑tl=0(Vl − V0)/V0]×
100%, where dt is the day in which the tth measurement was taken, V0 is tumor volume at day 0,
and Vl is tumor volume at measurement l taken on day dl (Gao et al., 2015). BAR is a measure of
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the maximum observed tumor shrinkage from baseline over measurements taken at least 10 days
after start of treatment, scaled by time since baseline. More negative values of BAR indicate a
better response. We used −BAR in the analysis so that larger values indicate a better response.
BAR mirrors similar criteria for assessing response in human clinical trials (RECIST, Therasse
et al., 2000). TTD is defined as the number of days from baseline that the tumor doubled in size
from its baseline measurement. Due to skewness in the distribution of TTD, we used the natural
log for analysis.
2.3 Implications of PDX Data for ITR Estimation
The unique structure of PDX data—the application of multiple treatments to mice implanted with
the same tumor—makes PDX data ideally suited for estimating optimal ITRs. Comparing responses
between mice within the same line does not amount to observing true treatment effects due to the
inherent variability that exists across mice; however, the improved precision of observing responses
to multiple treatments applied to the same tumor may substantially improve the performance of
estimated ITRs. The method we propose involves a sequence of decisions between two groups of
treatments. At each step, we aim to choose the group that contains the best treatment; thus,
the proposed method directly uses multiple responses within each line that would not be available
without PDX data.
Existing methods for estimating optimal ITRs have typically been designed for a small number of
treatments (two, for example). In this case, the set of treatments is large (20 or greater). Modeling
the conditional response is difficult in the presence of a large set of treatments due to the large
number of terms that would be included in the model. In a preclinical study like this, it is more
important to identify groups of promising treatments than to fully assess all pairwise comparisons
between treatments. Thus, we reduce the size of the treatment set by grouping treatments with
similar mean responses using hierarchical clustering. This allows us to adaptively create treatment
groups which have approximately similar treatment effects.
Finally, the set of genomic biomarkers is high-dimensional. Approximately 60,000 genomic
features are available, and many of the available features may exhibit either low variability or low
expression across samples. While some methods for estimating an optimal ITR can handle such high
dimension, we implement some common preprocessing steps similar to existing statistical methods
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in bioinformatics to reduce the dimension prior to ITR estimation. We also utilize some additional
steps to mitigate the ultra-high dimension of the predictor space, which we motivate and justify in
the next section.
3. METHODS
3.1 Overview
Let Y denote response and let X denote a vector of covariates. Let A = (A1, . . . , AJ) denote
treatment, where exactly one of A1, . . . , AJ is equal to 1 and the rest equal to 0, with Aj = 1
indicating that treatment j is given. The conditional mean response can be expressed as
E (Y |X = x, A = a) = h0(x) +
J∑
j=1
hj(x)aj . (1)
If we were to obtain estimators ĥj , j = 1, . . . , J , an estimator for the optimal ITR would be d̂(x) =
arg maxj=1,...,J ĥj(x). However, fitting model (1) nonparametrically in the PDX setting would be
difficult without large amounts of data, due to the large number of treatments and high dimension
of the covariate space. Therefore, we propose to impose structure on model (1) to ameliorate these
difficulties. The result is a multi-step procedure to reduce the dimension of the feature space,
reduce the size of the treatment set, and estimate optimal ITRs for the reduced treatment set
using the reduced feature space. The steps of our procedure are described in Sections 3.1.1-3.1.3
below. Various modeling decisions must be made at each step, and some alternative choices for
these decisions are discussed in Section 3.3. Because it is not immediately obvious what the optimal
set of modeling decisions is, we apply super-learning (Luedtke and van der Laan, 2016) to combine
variants of the proposed method with different embedded models. For complete details on our
methodology, we refer the reader to Section 7 of the Supplemental Materials.
3.1.1. Preprocessing (step 1). In the first step, we perform a preprocessing of genomic features to
remove features without sufficient variance (Supplemental Materials Section 7.1). Genomic features
are filtered out at this step due to low expression or low variability. This is a well-studied technique
for dimension reduction prior to analysis (Love et al., 2014; Bourgon et al., 2010; Soneson and
Delorenzi, 2013; Rashid et al., 2014). This screening is performed separately for each cancer type.
A summary of the number of genes and features remaining after this step is given in Supplementary
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Table 2. In addition, treatments applied in less than 90% of PDX lines within a cancer type were
filtered out for that cancer type (see Section 7.1 of the Supplemental Materials). We summarize the
number of treatments applied per PDX line per cancer after treatment filtering in Supplementary
Table 1.
3.1.2. Supervised screening (step 2). In the second step, we further reduce the dimension
of the feature space by selecting likely prognostic and predictive genomic features (Supplemental
Materials Section 7.2). Genes are ranked using Brownian distance covariance (Sze´kely et al., 2009),
evaluating the dependence between a vector of gene-level predictors for each PDX line and the
bivariate response (BAR, TTD) for a given treatment (prognostic) or difference in response between
a pair of treatments (predictive). After ranking genes, we select the top LSUP genes (LSUP =
50, 100, 500, 1000, Supplementary Table 2) and use all available platforms for the selected genes,
giving us pLSUP features corresponding to each value of LSUP. Screening in this way imposes
structure on model (1) by forcing the hj(x) to be constant in some of the covariates for certain
j = 0, . . . , J . This strategy helps to alleviate the difficulties caused by the large number of genomic
features and is similar in nature to sure independence screening (Fan and Lv, 2008), used in ultra-
high-dimensional regression problems to reduce the feature dimension to a more moderate size
prior to application of variable selection methods. All of our analyses are repeated for each of
LSUP = 50, 100, 500, 1000 top genes to yield insights into the performance of estimated ITRs based
on differing numbers of features. Screening is performed separately for each cancer type.
Because the set of genomic features consists of multiple platforms per gene, the feature set
resulting from selecting the top LSUP genes may still contain a large number of features. In addition,
predictors generated from different platforms (e.g., RNA-seq and copy number) on the same gene
may be correlated, and gene expression may be correlated across different genes. Thus, there
may be a lower-dimensional feature space that would be sufficient for ITR estimation. To address
this, we applied a further dimension reduction step using deep learning autoencoders (DAE, Wang
and Laber, 2017), a variant of deep neural networks (Vincent et al., 2010). See Section 7.3 of
the Supplemental Materials for details. This allows us to evaluate whether a lower dimensional
representation of the feature set improves ITR estimation at the cost of additional computational
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burden.
Deep learning autoencoders build a nonlinear prediction model to predict all feature variables
from a low-dimensional representation of the original features, with dimension chosen by cross-
validation. The reconstruction error of this approach is several orders of magnitude lower than
principal components analysis across cancer types, particularly for LSUP = 50, 100 (Supplementary
Tables 3 and 4). This indicates that linear dimension reduction techniques are not sufficient to
capture the information contained in the data. Dimension reduction using DAEs imposes structure
on model (1) by forcing the hj(x), j = 0, . . . , J to depend on x only through the low-dimensional
summary of the original features. The dimensions for each feature set following application of deep
learning autoencoders within each cancer are given in Supplementary Table 5. After applying steps
1 and 2 to obtain low-dimensional sets of covariates, we use the low-dimensional sets of covariates
to estimate optimal ITRs.
3.2 Estimation of Treatment Tree-based ITRs
Estimating an ITR to select from a large number of treatments is challenging for two reasons.
First, fitting model (1) in the presence of a large number of treatments would be difficult due to
the large number of treatment × feature interaction terms. Second, the resulting ITR would be
difficult to interpret and implement. Instead of an ITR which selects one treatment from the full
set of treatments, it would be more useful to have an ITR which selects a group of treatments from
a partition of the full set of treatments, where treatments in the same group can be expected to
lead to similar responses. Ideally, we would create groups of treatments such that the conditional
mean response function is the same for all treatments in the same group. However, this treatment
grouping is unknown. In Section 3.2.1, we describe a heuristic technique for approximating this
treatment grouping using hierarchical clustering. This allows us to create different groupings of
treatments by cutting the tree (the dendogram resulting from the clustering) in different places.
We then define a class of ITRs that can be expressed as a sequence of binary decisions, one for each
step of the tree. This tree structure is distinct from tree-based regimes which use a tree structure
to represent the final estimated ITR (Laber and Zhao, 2015; Zhang et al., 2015). A variety of
methods could be used to construct decision rules for each step of the tree. We introduce two: a
regression-based approach (Section 3.2.3) and a direct search approach (Section 3.2.4).
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3.2.1. Treatment tree construction. Denote the ith mouse corresponding to the jth PDX line
within the kth cancer type with subscript ijk, where k = 1, . . . , 5, j = 1, . . . ,mk, and i = 1, . . . , pjk,
with pjk representing the number of treatments applied to PDX line j in cancer type k, and
mk representing the number of PDX lines for cancer type k (Supplementary Figure 2). We let
Pk = maxj=1,...,mk pjk, i.e., for each PDX line, up to Pk mice were expanded to receive a maximum
of Pk treatments in cancer type k, one treatment applied per mouse (Supplementary Figure 3). For
certain lines, pjk < Pk treatments may have been applied, as the number of mice per line varied.
For ease of notation, we assume that pjk = Pk and that the ith mouse in each PDX line received
the same treatment within cancer type.
For treatment i in cancer k, we define the treatment response vector Yik = (Yi1k, . . . , Yimkk)
ᵀ,
where Yik is scaled to have standard deviation 1 (rows in Supplementary Figure 6, left panel).
Because there are inherent baseline differences in response between PDX lines, we first center the
response values of each PDX line (columns in Supplementary Figure 6, left panel) with respect
to the “null” response within each PDX line. Using PDX lines with Pk mice, we calculate the
Euclidean distances between Yik and Yi′k, i, i
′ = 1, . . . , Pk, i 6= i′ to get a distance between each
pair of treatments. For a fixed constant, c1, we group the c1 nearest neighbors of the “untreated”
treatment response vector to form a “null” set of treatments, denoted by Ak,c1,0, containing those
treatments producing low or no response. Then, for each i /∈ Ak,c1,0, we compute the mk× 1 vector
of centered observed outcomes, Rik = Yik − Y¯Ak,c1,0 , where Y¯Ak,c1,0 is the mk × 1 vector of averaged
treatment responses for each of the treatments in Ak,c1,0. Thus, Rik is the difference between the
response to treatment i and the average response in the null treatment group.
Next, we perform hierarchical clustering on the centered treatment response vectors and take
the resulting dendogram as a treatment tree (Supplementary Figure 6, right panel). For a fixed
constant, c2, we can construct treatment groups by cutting the tree c2 steps from the root node. For
cancer type k, we label the treatment groups determined by c1 and c2 as Ak,c1,1, . . . , Ak,c1,c2+1 and
denote the set of all possible treatment groups in cancer k given (c1, c2) by Ak,c1,c2 =
c2+1⋃
a=1
Ak,c1,a ∪
Ak,c1,0. Although Ak,c1,c2 depends on c1 and c2, we will write A in place of Ak,c1,c2 to simplify
notation. The hierarchical clustering groups treatments together when they result in similar mean
responses, in contrast to grouping treatments by predefined characteristics such as molecular target
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or mechanism of action. Grouping treatments in this way forces certain hj , j = 1, . . . , J in model (1)
to be equal, similar to a fusion penalty (Tibshirani et al., 2005). This strategy helps to alleviate
the difficulties caused by the large number of treatments and allows the estimated ITRs to select a
group of treatments likely to produce similar outcomes (Wu, 2016). We average responses within
the resulting treatment groups, yielding one response for each PDX line and treatment group in A.
An ITR can be estimated for each value of c1 and c2, and the optimal values of c1 and c2 can be
selected using cross-validation.
3.2.2. Identification of the optimal ITR. Let X ∈ X̂ ⊂ RpLSUP be the vector of genomic
features, where we write X̂ to make it clear that the domain of the feature space is data-dependent
(see Sections 3.1.1 and 3.1.2). An ITR is a mapping D : X̂ → A. For each treatment a ∈ A,
define the potential outcome R∗(a) to be the outcome that would be observed under treatment a
(Rubin, 1978). Within cancer type k, the set of potential outcomes consists of R∗ij(ai), i = 1, . . . , Pk,
j = 1, . . . ,mk. We make the assumption that E
{
R∗ij(a)
}
= E
{
R∗i′j(a)
}
for all i, i′ = 1, . . . , Pk,
all j = 1, . . . ,mk, and all a ∈ A. That is, we assume that the expected value of the potential
outcomes for mouse i and i′ from the same PDX line would be equal if they both received the same
treatment. The standard assumption of positivity is not needed because each PDX line is assigned
to every treatment used for that cancer type. On the other hand, while the standard assumption of
no unmeasured confounders is still needed in our setting, the primary source of confouding is due
to the assignment of mice to treatment within PDX line and not due to the genetic features of the
PDX line since each line receives all treatments. Hence we assume that the process of assigning
treatment to mice is exchangeable and homogeneous, and thus the no unmeasured confounding
assumption obtains. Define the value of an ITR, D, by V (D) = E (E [R∗ {D(X)} |X]). Let D
be the set of ITRs which can be expressed as a sequence of decision rules, one for each step of
the treatment tree, starting from the root node and proceeding until a leaf node is reached. The
optimal ITR associated with the treatment tree is D∗ = arg max
D∈D
V (D), i.e., the ITR that maximizes
value within the class.
3.2.3. Treatment tree-based Q-learning. In this section, we propose an extension of Q-learning
(Murphy, 2005; Zhao et al., 2009, 2011; Schulte et al., 2014) to estimate the optimal ITR associated
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with the treatment tree. Let aw(t), w = 0, 1 denote the set of treatment groups downstream to the
left (a1(t)) and right (a0(t)) arms of a node at step t, where t = c2, . . . , 0. Starting at the step corre-
sponding to the lowest node, we compute Rjw(c2) =
[∑Pk
i=1RijI {i ∈ aw(c2)}
]
/
∑Pk
i=1 I {i ∈ aw(c2)}
for j = 1, . . . ,mk and w = 0, 1. Here Rjw(c2) is the mean observed reward (centered response) in
PDX line j across the treatments belonging to treatment group aw(c2). We then fit a regression
model forRjw(c2) based onXjk, separately for w = 0 and w = 1, to obtain Êc2 [R
∗ {aw(c2)} |X = x],
the estimated conditional mean reward in treatment group w at step c2 given genomic features. If
either Rj0(c2) or Rj1(c2) are missing for a given line, then that line did not receive that particu-
lar treatment; these observations are removed before fitting the regression model. The estimated
optimal decision rule at step c2 of the tree for an individual with genomic features x is given by
D̂QLc2 (x) = argmax
w∈{0,1}
Êc2 [R
∗ {aw(c2)} |X = x] , (2)
i.e., the treatment group with the highest predicted clinical response given x is the estimated
optimal treatment group at step c2. We repeat the above process for step t = c2 − 1, . . . , 1, except
Rjw(t) only utilizes the observations for each PDX line from the optimal treatment group selected
at the previous step. Thus, the proposed method directly utilizes the multiple responses observed
for each PDX line.
Step t = 1 corresponds to the highest node in the treatment tree consisting of the non-null
treatments, and step t = 0 corresponds to the split between the null group (centered by their own
means) and the non-null treatments from the treatment tree. The decision rule is determined in
a similar manner at step t = 0, evaluating whether any non-null treatment should be applied. At
t = 0, the response vector for the null group is a vector of zeros, and the decision rule at this step
simplifies to determining whether the expected value of the response under the optimal non-null
treatment is greater than 0. A number of techniques could be used to fit the regression models at
each stage, representing different ways of imposing structure on the hj , j = 0, . . . , J in model (1).
We discuss various embedded models that could be used in more detail in Section 3.3.
Given the sequence of estimated decision rules
(
D̂QL0 , . . . , D̂
QL
c2
)
, the optimal treatment for a
new individual given their set of predictors is obtained by following the decision rules sequentially
from step t = 0 downward until one arrives at a terminal node on the tree. Rather than recom-
mending a sequence of treatments, as in standard Q-learning, the estimated optimal decision rule
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at each step of the tree directs the user through either the left or right arm at each node, creating
a path through the tree to arrive at a terminal node representing the optimal treatment group for
that individual.
3.2.4. Treatment tree-based outcome weighted learning. Outcome weighted learning (OWL)
estimates the optimal ITR for selecting between two treatments by maximizing an inverse prob-
ability weighted estimator of the value function over a fixed class of decision rules. Thus, unlike
Q-learning, OWL does not rely a fitted regression model. Our extension of OWL adopts the same
tree structure as in the previous section. However, instead of fitting a separate regression model
for each arm at split t, the optimal decision rule at split t is estimated directly using weighted
classification methods (Zhou et al., 2017; Liu et al., 2016; Chen et al., 2017). When treatment is
binary, any decision rule can be written as D(X) = sign {f(X)} for some decision function, f . We
will assume that the decision boundary at each split is smooth. Thus, at each split, we use a class
of decision rules defined by some class of smooth functions F , e.g., a reproducing kernel Hilbert
space. At the tth split of the treatment tree, let D̂OWLt (x) = sign
{
f̂t(x)
}
, where
f̂t = arg min
f∈F
Ent (|R| [I(R ≥ 0){1−Af(X)}+ + I(R < 0){1 +Af(X)}+]) + λnJ(f). (3)
Here, Ent denotes the empirical measure of the data used in the tth split, J(f) is a penalty term for
the decision function f , λn is a tuning parameter which is selected using cross-validation, and F is
a space of functions. As in Q-learning, the observations included when computing the minimizer
in equation (3) are all of those corresponding to the estimated optimal treatment group at the
previous step. Thus, our extension of OWL also directly utilizes the multiple outcomes observed
per PDX line. We discuss options for selecting F in Section 3.3; different options for F impose
different specific forms that the hj , j = 0, . . . , J must take in model (1).
3.2.5. Theoretical justification of tree-based ITRs. In this section, we show that the value of
the optimal ITR associated with a treatment tree increases strictly with each step down the tree,
until the step where there is no heterogeneity in conditional mean response for treatments within
the same group. Let G = {G1, . . . , Gp}, 1 < p ≤ Pk, be a grouping of treatments, that is, G is
a partition of the set of all Pk treatments. Conditioning hereafter on the selected set of features
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X̂ , let D : X̂ → G be an ITR, i.e., D(x) = G implies that treatment group G is selected for a
subject with features X = x. We assume that if D(x) = G, the decision maker will select one of
the treatments from G with equal probability. Define the value of D with respect to G to be
V (D;G) = E
[∑
G∈G
1 {D(X) = G} |G|−1
∑
a∈G
E {R∗(a)|X}
]
,
where |G| is the number of treatments in G. The optimal ITR is given by
D∗(x) = arg max
G∈G
|G|−1
∑
a∈G
E {R∗(a)|X = x}
and the value of the optimal ITR (also called the optimal value) is
V ∗ (G) = E
[
max
G∈G
|G|−1
∑
a∈G
E {R∗(a)|X}
]
.
We call a grouping (partition) G˜ =
{
G˜1, . . . , G˜m
}
finer than G if any G ∈ G can be written as the
union of sets in G˜. We obtain the following result:
Theorem 3.1. If G˜ is finer than G, then V ∗
(
G˜
)
≥ V ∗ (G). Furthermore, equality holds if and only
if, for any G˜ ∈ G˜ and G ∈ G such that G˜ ⊂ G,
∣∣∣G˜∣∣∣−1∑a∈G˜E {R∗(a)|X} = |G|−1∑a∈GE {R∗(a)|X}
with probability one.
Proof. For G ∈ G with G = ∪mj=1G˜j , we have for any x ∈ X̂ that
|G|−1
∑
a∈G
E {R∗(a)|X = x} = |G|−1
m∑
j=1
∑
a∈G˜j
E {R∗(a)|X = x}
=
m∑
j=1
(∣∣∣G˜j∣∣∣ /|G|) ∣∣∣G˜j∣∣∣−1 ∑
a∈G˜j
E {R∗(a)|X = x}
≤ max
j=1,...,m
∣∣∣G˜j∣∣∣−1 ∑
a∈G˜j
E {R∗(a)|X = x} .
The above holds with equality if and only if
∣∣∣G˜j∣∣∣−1∑a∈G˜j E {R∗(a)|X} is the same for all j =
1, . . . ,m, or equivalently,
∣∣∣G˜j∣∣∣−1∑a∈G˜j E {R∗(a)|X} = |G|−1∑a∈GE {R∗(a)|X} for all j = 1, . . . ,m,
with probability one.
Theorem 3.1 states that a finer partition of treatments never leads to a decrease in value of the
optimal ITR and that the change in value of the optimal ITR is zero only when the conditional
mean response is constant across treatments within groups in the finer partition.
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Theorem 3.2. For a grouping G and any set G ∈ G, further partition G into two nonempty groups
G1 ∪G2 to obtain a finer partition, G˜. If for any such finer partition, G˜, V ∗
(
G˜
)
= V ∗(G), it holds
that
E {R∗(a1)|X} = E {R∗(a2)|X}
with probability one for all a1, a2 ∈ G.
Proof. From Theorem 3.1, we obtain that for any G1 and G2 such that G = G1 ∪G2,
|G1|−1
∑
a∈G1
E {R∗(a)|X} = |G2|−1
∑
a∈G2
E {R∗(a)|X} ,
with probability one. Suppose that the proposition does not hold. Then, there exists some
a1, a2 ∈ G such that E {R∗(a1)|X = x0} 6= E {R∗(a2)|X = x0} for all x0 ∈ X0 for some X0 ⊂ X̂
with positive probability. For any x0 ∈ X0, order the ai ∈ G such that E {R∗(ai)|X = x0} are
nondecreasing with at least two adjacent values different, say positions l and l + 1 in the ordered
sequence. Then, if we let G1 = {a1, . . . , al} and G2 = {al+1, . . . , aq}, we obtain that
|G1|−1
∑
a∈G1
E {R∗(a)|X = x0} > |G2|−1
∑
a∈G2
E {R∗(a)|X = x0} ,
for all x0 ∈ X0. Because X0 has positive probability, this creates a contradiction.
Theorem 3.2 implies that if no binary splits at one branch will lead to an increase in the optimal
value, then all treatments within that branch are homogeneous with respect to conditional mean
response. Thus, each further partition created by cutting the tree at a lower step will lead to an
increase in the optimal value function until there is no heterogeneity in response across treatments
in the same group.
3.3 Modeling Decisions
The framework proposed in this paper involves creating a tree of treatments using hierarchical
clustering and estimating an ITR as a sequence of binary decisions, one for each step of the tree.
Within this general framework, there are a number of specific modeling decisions that need to
be made. In this section, we describe different variants of the proposed method that result from
making different modeling decisions.
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The tree-based ITR estimation method involves an embedded method to estimate the optimal
decision rule at each step. Fitting a regression model at each step results in an extension of
Q-learning (see Section 3.2.3). A number of regression models could be used as the embedded
regression model; in our analyses, we used linear models with a LASSO penalty and random forests.
In Section 4, these are referred to as QL and QLRF, respectively. At each split, our extension of
Q-learning uses the maximum outcome across treatments downstream to the left and right of the
split as the observed outcomes when fitting the regression model. Alternatively, we could obtain
predicted maximum outcomes using the regression model and use the predicted maximum outcomes
to fit the model at the next step. These are analogous to the pseudo-values used in standard versions
of Q-learning (Zhao et al., 2009, 2011), and would allow application of the proposed tree-based Q-
learning method to data that do not come from a PDX study. We examine both strategies in
Section 4, and we refer to Q-learning with observed outcomes and with pseudo-values as QL1 and
QL2, respectively.
Constructing an inverse probability weighted estimator (IPWE) at each step, rather than fitting
a regression model (as in Q-learning), results in an extension of OWL (see Section 3.2.4). The IPWE
is maximized over a class of functions. We use both the class of linear functions and the reproducing
kernel Hilbert space associated with the Gaussian kernel function (Zhao et al., 2012; Chen et al.,
2017). In Section 4, these are referred to as OWLlinear and OWLkernel, respectively.
The second modeling decision that must be made is the selection of the covariate set. We applied
the proposed method using the pLSUP dimensional set of genomic features resulting from screening
using Brownian distance covariance, for each LSUP = 50, 100, 500, 1000 (Supplementary Table 1).
We also applied the proposed method to the lower dimensional set of features extracted from LSUP
genes using the DAE, for each LSUP = 50, 100, 500, 1000 (Supplementary Table 5). Analyses using
the features extracted from the DAE are labeled with the subscript “dl” in Section 4.
A final variant of the method that we explored involves replacing the observed outcomes with
model-predicted outcomes before estimation. We fit a random forest to predict outcomes based
on covariates alone (features and treatments) and replaced the observed outcomes with predictions
based on the fitted model for all later stages of the analysis. This approach acts to denoise the
observed outcomes. Analyses utilizing this approach are labeled with the subscript “smoothed”.
17
In Section 4, we report analyses using different combinations of the modeling decisions described
above to capture synergistic effects of the various modeling decisions. In addition to estimating
tree-based ITRs as proposed in Section 3.2.1, we also estimated ITRs by fitting model 1 using linear
models with the LASSO penalty and random forests. These “off-the-shelf” methods were included
to compare to the proposed method.
3.3.1. Super-learning. The various modeling decisions outlined in Section 3.3 above result in
many variants of the proposed method. While certain variants may work better than others in
certain settings, the optimal choice of modeling decisions may not always be clear. A natural
analysis to try in this case is to combine a set of input ITRs estimated using various embedded
models in the hopes that the resulting ITR performs better than any of the input ITRs. To
accomplish this, we apply the super-learning algorithm of Luedtke and van der Laan (2016). Briefly,
Luedtke and van der Laan (2016) propose combining a number of existing methods using cross-
validation to calculate a linear combination of latent functions to maximize the value function.
In our implementation, there is not an explicit latent function due to the fact that we are using
a sequential treatment tree as our model. To approximate the value of the latent function with
respect to a single treatment, we utilize the predicted reward from one of our sub-models at a given
node in the tree whose direct children include our goal treatment. To optimize the superlearner, we
use simulated annealing to estimate the coefficients. Multiple chains are used whose starting points
are selected from a set of randomly generated coefficients. In Section 4, variants of super-learning
with different sets of input ITRs are referred to with the subscript sl, followed by the number of
ITRs that are combined to produce the superlearner.
3.4 Performance Measures for Individualized Treatment Rules
We used five fold cross-validation to evaluate the performance of ITRs estimated using the proposed
method with the various modeling decisions as described in Section 3.3. Within each cancer type,
we divided PDX lines into five folds. An optimal ITR was estimated using the training data set
that results from holding out each fold, and the estimated value was calculated on the held-out fold
as En
[
RI
{
A = D̂∗ (X)
}]
/En
[
I
{
A = D̂∗ (X)
}]
, where En denotes the empirical measure taken
over mice in the held-out fold. Tuning parameters (such as c1 and c2 for estimating tree-based
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ITRs and the OWL penalty parameter) were selected using cross-validation within each training
data set. The estimated value of the estimated ITR, denoted by V¯
(
D̂∗
)
is calculated by averaging
the value estimates resulting from each fold. We also calculated the standard deviation of value
estimates across folds.
Different cancer types may result in different marginal mean outcomes. To facilitate com-
parisons across cancer types, we also computed the observed value, Vobs, defined as the sample
average of centered responses for all mice that received non-null treatments, and the optimal value,
Vopt, defined as the sample average across PDX lines of the maximum centered response across
treatments, i.e., Vopt = m
−1
k
∑mk
j=1 maxi=1,...,PkRijk. The observed value and optimal value can be
used to define two metrics for evaluating estimated ITRs: proportion of optimal value, defined as
Popt
(
D̂∗
)
= V¯
(
D̂∗
)
/Vopt, and ratio to observed value, defined as Pobs
(
D̂∗
)
= V¯
(
D̂∗
)
/Vobs.
4. RESULTS
All analyses were performed separately for each cancer type. We applied various combinations of
the modeling decisions outlined in Section 3.3. Each modeling variant was applied to the feature
set resulting from screening with different values of LSUP (see Section 3.1.2), utilizing the original
features or the features extracted from the DAE. We present results for BAR and defer results for
TTD to Section 5 of the Supplemental Materials.
Figure 1 illustrates the strong linear relationship between the mean value under each estimated
ITR and the optimal value for the associated cancer type and treatment grouping. Note that in
the majority of cases the optimal values do not vary within a cancer type. However, in some cases
there is variability in the optimal value due to the fact that we select c1 and c2 separately for
each analysis. Each point in Figure 1 represents a particular estimated ITR within a particular
cancer. We also observe a similar relationship between the mean and observed values for each
estimated ITR. This suggests that the marginal mean outcome differs across cancer types. This
is not unexpected, as some cancers are known to be more sensitive to available treatment options
(e.g., CM), and others less so (e.g., PDAC). This observation motivates our use of Popt
(
D̂∗
)
and
Pobs
(
D̂∗
)
to evaluate performance of estimated ITRs. We present results for Popt
(
D̂∗
)
here and
defer results for Pobs
(
D̂∗
)
to Section 4 of the Supplemental Materials.
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[Figure 1 about here.]
4.1 Relative Performance of Methods Pooling Across Conditions
We summarize Popt
(
D̂∗
)
for each variant of the proposed methods and the “off-the-shelf” methods
in Figure 2, pooling results across different cancer types and values of LSUP. From this figure,
several striking trends are apparent. For example, the application of data smoothing prior to ITR
estimation boosts the overall performance for many methods, such as Q-Learning with embedded
linear models (light and dark green), and OWL methods (light and dark grey). This pre-smoothing
is less beneficial for Q-Learning methods utilizing embedded random forests (salmon and red), as
the pre-smoothing itself is performed using random forests. Q-learning methods using pseudo-values
(red, QL2) performed similarly to their QL1 counterparts (pink) across conditions. In general, Q-
learning performed better than OWL overall across variable conditions. In addition, using the lower
dimensional features extracted from the DAE did not show significant benefit for most approaches
with the exception of the OWL methods using the linear kernel, which we will show later to be
sensitive to the dimension of the feature space. Q-Learning methods with non-linear embedded
models (salmon, red) showed much better robustness to various modeling choices than linear ones,
and showed to be especially helpful in OWL (dark grey). Lastly, simpler off-the-shelf methods
showed lower performance and much higher variability across conditions compared to methods
utilizing the treatment tree approach. Relative to the LASSO, almost all methods utilizing the
treatment tree performed better than the simpler off the shelf methods.
We also find that utilizing a weighted combination of ITRs using the superlearner approach
(dark blue) resulted in the best overall performance across conditions. Increasing the number
of ITRs included in the superlearner had the effect of boosting performance while also reducing
variability in performance across conditions. Here, the SL4 combined all four Q-Learning methods
from Fig 2 utilizing pre-smoothing, SL6 includes the addition of methods QL1,RF and QL2,RF,
SL8 adds QL1 and QL2, and SL16 add all Q-learning methods utilizing DAE features. OWL
methods were excluded from the superlearner due to computational time, and we expect additional
performance increases through their inclusion. This suggests that the superlearner approach can
boost performance and also mitigate user uncertainty regarding the selection of various modeling
approaches in cases where the optimal approach may not be clear beforehand.
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The examination of pooled overall and relative performance in Figure 2 is informative when
the analyst is unsure what approach is best for their data and wants to use the “safest” approach.
For example, the results in Figure 2 can be used to determine a sequence of modeling decisions
that exhibited good overall performance across a variety of conditions and achieved low variabil-
ity across conditions. For example, QL1, smoothed, or Q-learning utilizing smoothed outcomes and
observed-values, achieved good performance on average and low variability in performance across
conditions. Alternatively, one may elect to combine ITRs from multiple methods using the super-
learner approach to avoid choosing an individual method, at the cost of additional computational
burden. In addition, our results suggest the following general conclusions: linear methods may
benefit from the use of data smoothing prior to ITR estimation, further dimension reduction of
the predictor space via DAEs is beneficial for OWL methods using the linear kernel, and nonlinear
embedded models are more robust to various modeling choices than linear embedded models.
[Figure 2 about here.]
4.2 Impact of LSUP on Performance
We now examine the relative performance of our estimated ITRs by LSUP, the number of genes
used in estimation. Figure 3 contains boxplots of Popt
(
D̂∗
)
pooled over cancer types and stratified
by estimation method and LSUP (Supplementary Table 1). Prior to pooling we adjust Popt
(
D̂∗
)
in each cancer type and method by the performance at Popt
(
D̂∗
)
= 50 to more clearly delineate
changes with respect to dimension. Most methods did not show strong trends in performance across
LSUP, with the exception of the OWLlinear class of methods (light grey). In this class, Popt
(
D̂∗
)
decreases with increasing numbers of genes. However, the same trend did not appear when utilizing
the Gaussian kernel. Slight downward trends were also observed for Q-learning with an embedded
linear model (light and dark green). These observations together suggest that methods in which a
linear decision rule is estimated at each step of the treatment tree may be sensitive to the dimension
of the feature space.
The optimal set of features for ITR estimation (indexed by LSUP) is the set of all those features
for which at least one of the hj , j = 0, . . . , J in model (1) is not constant. While the optimal
set of features is unknown, the results in Figure 3 indicate that the proposed treatment tree-
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based ITR estimation method performs well regardless of the number of features selected, with the
exception of linear OWL and Q-learning with an embedded linear model. These results lead to the
conclusion that a smaller set of features post-supervised screening may be optimal for methods with
an embedded linear model, and an embedded nonlinear model can be used to provide robustness
against selecting the “wrong” set of features.
[Figure 3 about here.]
4.3 Overall Performance by Cancer
The performance resulting from specific modeling decisions varies across cancer types. Figure 4
contains boxplots of Popt
(
D̂∗
)
for the best performing set of modeling decisions within the classes
defined by the colors in Figure 2. To select the best performing variant in each class, we chose
the one with the largest Popt
(
D̂∗
)
averaged across values of LSUP within that particular class.
The boxplots in Figure 4 contain Popt
(
D̂∗
)
over values of LSUP. We show the full set of results
corresponding to all methods and cancers in the Section 3 of the Supplemental Materials. Within
certain cancers, such as breast cancer (BRCA), specific modeling decisions do not result in large
differences in performance. This may be due in part to the fact that a small number of treatments
appear to work well uniformly across samples in BRCA (Supplementary Figure 8). In contrast,
for pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC), greater heterogeneity in
response exists across treatments (Supplementary Figures 9 and 10). In addition, we find that
in almost all cancer types, the superlearner tended to perform better than or similar to all other
classes of methods, suggesting its use when it is unclear which individual method may be optimal
for a particular dataset.
Table 1 lists the best overall set of modeling decisions for each cancer type, along with the
genomic features that were most important for selecting treatments using the best performing
estimated ITR. For cancers where the best performing ITR resulted from the DAE predictors or
OWL methods using the Gaussian kernel, it is difficult to determine which genes were the most
important. For these cases, we selected important features using the second-best ITR (Reference
Method in Table 1). For all cancer types, the best performing ITR resulted from the tree-based
approach rather than an “off-the-shelf” method. In addition, despite their sensitivity to dimension,
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the OWLlinear class of methods were represented as the best ITR in two out of five cancers. This
suggests that as long as the correct feature dimension is selected beforehand, OWL method can
perform well relative to other methods. In practice however, the optimal dimension is difficult to
ascertain unless one evaluates multiple candidate feature sets, as we have in this manuscript.
The treatments most frequently recommended by the best performing ITR for each cancer, along
with the corresponding values of c1 and c2, are given in Supplementary Table 6. The treatment
tree for the optimal ITR varied in the values of c2 across cancer types, suggesting variability in
the amount of response heterogeneity across cancer types. For example, in CM, where response
tended to be strong overall (Figure 1), c2 = 9, suggesting that relatively more treatments had
similar response profiles across PDX lines. The selected value of c1 for the best performing ITR
was low for each cancer type, indicating that only a small number of treatments were found to be
effectively the same as “untreated” based on the hierarchical clustering (Supplementary Table 6).
For “off-the-shelf” methods, c1 = 0 and c2 = Pk by design since no grouping of treatments was
performed.
We list the average (unconditional) response for each of the Pk treatments within cancer type
in Supplementary Table 8, calculated as the sample average response across mice treated with each
of the Pk treatments across PDX lines. In BRCA, the treatment with the larger mean response
was also the most recommended treatment (LEE011 + everolimus). In PDAC, however, there is
less variability in average response across treatments, and the best performing ITR recommends
BKM120 + binimetinib to 18 PDX lines and abraxane + gemcitabine to 18 PDX lines (see Sup-
plementary Table 7).
[Figure 4 about here.]
[Table 1 about here.]
4.4 ITR Performance When Limiting Features to a Single Genomic Platform
The three genomic platforms utilized in this study provide a wealth of information for ITR estima-
tion and biomarker discovery. However, the high dimension of the feature space provides practical
and computational challenges. Predictors from the same gene may be correlated (for example, gene
expression and gene copy number) and may therefore be redundant. Evaluating three genomic
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platforms for each PDX line’s original tumor increases cost and amount of tumor tissue required.
For these reasons, we also explored the performance of ITRs estimated using only the RNA-seq gene
expression platform, a common genomic assay performed by biomedical researchers. We repeated
the same process described in Section 3, but using only features resulting from RNA-seq.
The overall conclusions are largely similar to those in Figure 2 (see Supplementary Figure 11).
When we compare the difference in Popt
(
D̂∗
)
between the ITR estimated using the full feature set
and the ITR estimated using RNA-seq only, we find that most methods perform similarly using only
RNA-seq data (Supplementary Figure 12). Q-learning and OWL methods with embedded linear
models did slightly better than corresponding ITRs trained on all three platforms, which is likely
related to the relative sensitivity of these methods to the dimensions of the feature space (smaller
in the RNA-seq only analysis). Otherwise, most methods evaluated in RNA-seq only performed
similarly to ITRs trained on all three platforms. Due to the smaller feature space in the RNA-seq
only analysis we did not elect to run the deep learning variants of each method. Overall, these
results suggest that utilizing a single genomic platform may be a more cost-effective option that
will result in estimated ITRs with comparable performance.
4.5 Top Genomic Features in NSCLC
Lung cancer is one of the leading causes of cancer related deaths in the United States, and NSCLC
accounts for the majority of clinical cases of lung cancer (Ettinger et al., 2010). Therapeutic agents
used to treat NSCLC include paclitaxel, which interferes with cellular microtubular dynamics and
cellular division through the targeting of tubulin (Wise et al., 2000), and cetuximab, which targets
the epidermal growth factor receptor (EGFR) (Pirker et al., 2009). Since the mechanism of action
differs between these two treatments, it is not surprising that we observed significant heterogeneity
in response between these two treatments in this study (Supplementary Figure 10). Here, we
examine the relationship between response and the genomic features found to be the most important
for making decisions using the best performing estimated ITR.
The best performing ITR for NSCLC resulted from OWLkernel,smoothed (see Table 1). Given
that that gaussian kernel for OWL does not allow direct interpretation of its predictors, we utilize
the reference method QL2,smoothed in this cancer to examine the role of each selected predictor
with respect to response. We determined the most important genomic features for this ITR using
24
the following approach. For each of the c2 splits in the associated treatment tree, we computed
the absolute value of the regression coefficient for each feature in the model fit at a given node
and retained the feature with the largest magnitude value at each node. Cross-validation selected
c2 = 13; therefore, we retained a set of 13 top features, where 10 of these were unique (Figure 5). We
then calculated Spearman’s rank correlation coefficient between each selected feature and response,
separately within each non-null treatment. This resulted in the matrix of feature-treatment pairwise
correlation coefficients seen in Figure 5. We then clustered the columns of this matrix, pertaining
to the seven selected genomic features, using Euclidean distance between the vector of correlation
coefficients in each column. We also clustered the rows of this matrix, pertaining to the non-null
treatments, using the tree structure that was previously constructed for QL2,smoothed, rather than
the correlations.
The treatment with one of the strongest correlation to Tubulin Gamma 1 (TUBG1) copy number
is the therapy paclitaxel, suggesting that a higher copy number of TUBG1 may potentiate response
in patients being targeted with agents such as paclitaxel. This is notable because paclitaxel directly
targets tubulin (Kumar, 1981), of which TUBG1 plays a major role. Furthermore, cetuximab is
the only treatment that is anticorrelated with TUBG1 copy number. This unique relationship with
TUBG1 is reflected in the treatment tree, as cetuximab is the only member of a branch furthest away
from all other non-null treatments. Cetuximab also exhibits a unique mechanism of action, as the
only monoclonal antibody EGFR inhibitor in our data set. The relationship between TUBG1 copy
number and response to cetuximab and paclitaxel is displayed in Figure 5. These results indicate
that that the observed correlations between treatment response and the top features determined
from QL2,smoothed reflect the role these features play as important variables in the best performing
ITR.
[Figure 5 about here.]
5. DISCUSSION
In this paper, we introduced several approaches to ITR estimation using PDX data. The unique
structure of a PDX study, where multiple treatments are applied to samples from the same human
tumor implanted into mice, naturally lends itself to precision medicine. The substantially improved
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precision that results from the PDX structure may result in better performing ITRs. However,
PDX data also pose a number of challenges, including a large number of unordered treatments
and a high-dimensional feature space. These factors make it difficult to nonparametrically model
the conditional mean of the response. The method we propose involves of sequence of steps that
alleviate these difficulties. Our method involves screening the covariates to find a lower dimensional
feature space, constructing a treatment tree that allows for recasting ITR estimation as a sequence
of binary decisions, and estimating a decision rule at each split to select the arm that contains
the optimal treatment. Because we aim to select the arm that contains the optimal treatment at
each split rather than the arm with the largest average response, our estimation technique utilizes
the maximum response downstream of each arm for each line. Thus, our estimation technique
incorporates the unique structure of the PDX data by directly using the multiple responses observed
per PDX line. We’ve shown that the method we propose not only produces high-quality ITRs, but
also identifies genes that are known to be associated with response to treatment (e.g., the TUBG1
gene shown in Figure 5).
The methods we propose requires making a number of modeling decisions at various stages of
the pipeline, including selecting the dimension of the feature space, choosing embedded models, and
selecting tuning parameters, among others. We demonstrated various combinations of these model-
ing decisions in our analyses. While certain variants performed better than others for certain cancer
types, the treatment tree-based approach outperformed “off-the-shelf” methods overall. Reducing
noise by using random forest-predicted outcomes (smoothing) improved performance of the esti-
mated ITRs in most settings, and basing ITRs on DAE-extracted features improved performance
in the presence of a linear embedded model. In particular, Q-learning with smoothed outcomes
and pseudo-values performed well across all settings and is a good first choice for estimating ITRs
from PDX data. We recognize that the models, tuning parameters, and implementation discussed
here, despite our best efforts, may not be optimal. The method studied here could potentially
be improved through careful tuning. Studying the proposed method further, including through
extensive simulation experiments, could yield more concrete recommendations as to which embed-
ded models perform best. Our implementation of a superlearner consisting of multiple estimated
ITRs was shown to improve performance above individual ITRs. This approach helps mitigate
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user uncertainty regarding the best choice of ITR estimation approach or modeling choices for a
given problem, where one may combine the results from multiple ITRs using the superlearner for
improved performance.
Many of the modeling decisions in this paper were made with computational intensity in mind.
In our analyses, we utilized two large computing clusters at the University of North Carolina
at Chapel Hill, the Killdevil cluster with 9500 computing cores and the Longleaf cluster with
3600 computing cores. Future improvements on the proposed method must be implemented in a
computationally efficient way. We also recognize that there are many methods we could have used
that may have performed better, and that different methodological approaches entirely may be able
to improve upon these results. Nevertheless, the analyses in this paper demonstrate the potential
for using PDX studies to inform precision medicine.
The assumption that ITRs estimated from PDX data are applicable to humans is crucial to this
work. This assumption is based on decades of biomedical research on generalizing PDX results to
humans. A major conclusion of Gao et al. (2015) was that the responses observed in their PDX
lines correlated with the responses observed in the human patients from which the tumors were
taken. Many prior studies have shown that PDX models show stronger correlation with human
response compared to traditional cell line models (Whittle et al., 2015; Scott et al., 2014; Rosfjord
et al., 2014). Prior work has also shown that the tumor microenvironment, consisting of stromal
cells and other tissue, may impact tumor activity and response to treatment. In PDX models, the
microenvironment surrounding the implanted human tumor is non-human. However, several recent
studies have suggested that tumor recruitment of mouse stroma in PDX models mirrors that seen
in humans (Roife et al., 2016; Wang et al., 2017) and may show similarity in treatment response
when specifically targeted.
A key next step for this research will be to plan and conduct validation studies in humans to
determine if the biomarkers and ITRs discovered here can be used to improve outcomes in human
patients. We note that ITRs based on only one genomic platform (RNA-seq) resulted in comparable
performance to ITRs based on three genomic platforms. Since independent validation studies will
be more expensive if more genomic platforms are needed, validating the ITRs based only on RNA-
seq data using a study of human cancer patients would be a low-cost initial step toward validating
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the results in this paper. One advantage of the proposed method is that, in some settings, we
could apply the estimated ITRs to external studies that included only a subset of the treatments
applied in this study. Given a sequence of decision rules (pertaining to each step of the treatment
tree), one could start at the lowest node that contains all of the treatments of interest and follow
the tree to arrive at a recommended treatment, rather than starting from the top of the tree. We
also note that, while our results allow for comparing the performance of estimated ITRs across
different cancer types and modeling strategies, the data utilized for this paper do not allow for
comparing the performance of ITRs estimated from PDX studies to ITRs estimated from human
trials. Another important step forward for validating these results will be to compare the treatment
rules discovered here to those estimated from human trials to determine the value of PDX studies
for precision medicine.
The design of a PDX study plays a key role in ITR estimation, and designing high-quality PDX
studies is another key next step for this research. Our results suggest that the observed responses
in PDX studies are noisy. Having replicates within PDX line, i.e., multiple mice per line assigned
to the same treatment, may improve the performance of the estimated ITRs. The design could also
be improved by having a larger number of distinct tumor lines to ensure sufficient representation
of cancer heterogeneity across a diverse spectrum of cancer patients.
While our research has, in some ways, raised more questions than it has answered, we feel
that the treatment rules, biomarkers, and other results we have discovered here are interesting in
their own right and merit further research, including validation studies. Future research in this
area will allow us to make measurable advances in applying PDX studies in precision medicine and
translating the results into clinical practice. Plans for such future research is underway.
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Figure 1: Original (left) and scaled (right) values (for best average response) from all analyses, across
methods, cancer types, and LSUP. Optimal values for each method vary significantly by cancer
type. The value of each estimated ITR is correlated with the optimal value across cancer types.
We normalize the estimated value for each method by the optimal value to allow for comparisons
between cancers. The metric, called “proportion of optimal,” provides a measure of how close the
value of an estimated ITR is to the optimal value.
35
Pr
op
or
tio
n 
of
 O
pt
im
al
 (S
ca
led
 Va
lu
e)
0.
0
0.
4
0.
8
LA
SS
O
LA
SS
O
 D
L
R
F
R
F 
D
L
QL
1
QL
DL
1
QL
1S
M
OO
TH
QL
1S
M
OO
TH
D
L
QL
2
QL
DL
2
QL
2S
M
OO
TH
QL
2S
M
OO
TH
D
L
QL
RF
1
QL
RF
DL
1
QL
RF
1S
M
OO
TH
QL
RF
1S
M
OO
TH
D
L
QL
RF
2
QL
RF
DL
2
QL
RF
2S
M
OO
TH
QL
RF
2S
M
OO
TH
D
L
OW
LL
IN
EA
R
OW
LL
IN
EA
R
D
L
O
LW
LI
N
EA
R
SM
O
OT
H
O
LW
LI
N
EA
R
SM
O
OT
H
D
L
O
LW
KE
R
N
EL
OW
LK
ER
N
EL
D
L
OW
LK
ER
N
EL
SM
O
OT
H
OW
LK
ER
N
EL
SM
O
OT
H
D
L
SL
4
SL
6
SL
8
SL
16
N
or
m
a
liz
e
d 
to
 L
AS
SO
−
0.
2
0.
0
0.
2
0.
4
LA
SS
O
LA
SS
O
 D
L
R
F
R
F 
D
L
QL
1
QL
DL
1
QL
1S
M
OO
TH
QL
1S
M
OO
TH
D
L
QL
2
QL
DL
2
QL
2S
M
OO
TH
QL
2S
M
OO
TH
D
L
QL
RF
1
QL
RF
DL
1
QL
RF
1S
M
OO
TH
QL
RF
1S
M
OO
TH
D
L
QL
RF
2
QL
RF
DL
2
QL
RF
2S
M
OO
TH
QL
RF
2S
M
OO
TH
D
L
OW
LL
IN
EA
R
OW
LL
IN
EA
R
D
L
O
LW
LI
N
EA
R
SM
O
OT
H
O
LW
LI
N
EA
R
SM
O
OT
H
D
L
O
LW
KE
R
N
EL
OW
LK
ER
N
EL
D
L
OW
LK
ER
N
EL
SM
O
OT
H
OW
LK
ER
N
EL
SM
O
OT
H
D
L
SL
4
SL
6
SL
8
SL
16
Figure 2: Overall performance across methods, pooled over cancer types and number of features
(top). Popt(D̂
∗) for each method is also normalized to the LASSO in each condition to highlight
the relative performance of each approach (bottom). This relative measure was constructed by
subtracting the Popt(D̂
∗) pertaining to the LASSO from that of the other methods within each
combination of cancer type and LSUP value.
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Figure 3: Overall trends in performance for each method across LSUP, aggregated over cancer types.
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Figure 4: Performance of the best estimated ITR in each class across cancer types.
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Figure 5: Top genomic features selected by QL2,smoothed in NSCLC. Cells are colored by the mag-
nitude of their Spearman’s correlation between response to treatment (rows) and expression of top
features (columns). Genomic features were clustered by their vector of Spearman’s correlation to
each treatment (using Euclidean distance), whereas treatments were grouped based on the treat-
ment tree constructed for QL2,smoothed. The patterns of treatment-feature correlations tended to
coincide with the predetermined treatment groupings.
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CRC ql1smooth 100 ql1smooth FGG.rna,ALPK1.rna,WDR27.cn,DIDO1.mut,C10orf26.rna
NSCLC owlkernelsmooth 100 ql2smooth POFUT2.rna,TNNI3.cn,TUBG1.cn,NAT8L.cn,PTPRE.cn
PDAC ql1smooth 100 ql1smooth CTH.rna,DUSP4.cn,TPP2.rna,ACVR1B.rna,ZNF264.cn
Table 1: Best performing method and number of predictors for each cancer. Top 5 most important
predictors are listed. Predictors pertaining to the next best performing method were provided if
the top performing method utilized deep learning (Reference Method). Predictors ending in .rna
are from the gene expression data, .cn from the copy number data, and .mut from the mutation
dataset.
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